Data / Drug companies / Biocon Pharma Inc.
Biocon Pharma Inc.: 90 products in the FDA NDC directory, labeler code 70377
Biocon Pharma Inc. (labeler code 70377) lists 90 products in the FDA National Drug Code Directory, covering 32 finished drugs by generic name. By type: 90 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 25, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70377
- Products in commercial distribution
- 90
- Packages
- 194
- Finished drugs by generic name
- 32
- Prescription products
- 90
- Over the counter products
- 0
- Flagged as original packager
- 57 of 57 products that carry the flag
- Started marketing in the last 12 months
- 15
- Earliest marketing start
- December 17, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 90 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 90 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Everolimus | 11 | 15 |
| Lenalidomide | 6 | 19 |
| Dasatinib | 6 | 18 |
| Simvastatin | 5 | 32 |
| Pravastatin sodium | 4 | 39 |
| Labetalol hydrochloride | 4 | 43 |
| Atorvastatin calcium | 4 | 59 |
| Mycophenolic acid | 4 | 16 |
| Rosuvastatin calcium | 4 | 34 |
| Sacubitril and valsartan | 3 | 29 |
| Liothyronine sodium | 3 | 19 |
| Eltrombopag olamine | 3 | 7 |
| Tacrolimus | 3 | 35 |
| Prazosin hydrochloride | 3 | 35 |
| Aminocaproic acid | 3 | 23 |
| Teriflunomide | 2 | 17 |
| Triamterene | 2 | 4 |
| Dapagliflozin | 2 | 26 |
| Micafungin | 2 | 6 |
| Sertraline hydrochloride | 2 | 55 |
| Esomeprazole magnesium | 2 | 77 |
| Liraglutide | 2 | 11 |
| Deflazacort oral | 1 | 3 |
| Oxcarbazepine | 1 | 46 |
| Posaconazole | 1 | 29 |
| Nitrofurantoin | 1 | 28 |
| Famotidine | 1 | 138 |
| Fingolimod | 1 | 18 |
| Tofacitinib | 1 | 23 |
| Norepinephrine bitartrate | 1 | 25 |
| Daptomycin | 1 | 25 |
| Eltrombopag | 1 | 11 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 34 | 37.8% |
| Tablet | 17 | 18.9% |
| Capsule | 17 | 18.9% |
| Tablet, delayed release | 5 | 5.6% |
| Suspension | 3 | 3.3% |
| Injection, powder, lyophilized, for solution | 3 | 3.3% |
| Tablet, for suspension | 3 | 3.3% |
| Capsule, delayed release | 2 | 2.2% |
| Injection, solution | 1 | 1.1% |
| Solution | 1 | 1.1% |
| Powder, for suspension | 1 | 1.1% |
| Tablet, film coated, extended release | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Deflazacort Oral Suspension | 70377-188 | Suspension | Generic drugs (ANDA) | September 25, 2026 |
| Eltrombopag | 70377-186 | Tablet, film coated | Generic drugs (ANDA) | September 9, 2026 |
| Eltrombopag | 70377-185 | Tablet, film coated | Generic drugs (ANDA) | September 9, 2026 |
| Eltrombopag | 70377-184 | Tablet, film coated | Generic drugs (ANDA) | September 9, 2026 |
| Eltrombopag | 70377-183 | Tablet, film coated | Generic drugs (ANDA) | September 9, 2026 |
| Tofacitinib XR | 70377-057 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 3, 2026 |
| Dapagliflozin | 70377-024 | Tablet, film coated | Generic drugs (ANDA) | May 1, 2026 |
| Dapagliflozin | 70377-023 | Tablet, film coated | Generic drugs (ANDA) | May 1, 2026 |
| Liraglutide | 70377-094 | Injection | Generic drugs (ANDA) | April 25, 2026 |
| Liraglutide | 70377-095 | Injection, solution | Generic drugs (ANDA) | March 27, 2026 |
| Sertraline HCl | 70377-129 | Capsule | Generic drugs (ANDA) | January 30, 2026 |
| Sertraline HCl | 70377-128 | Capsule | Generic drugs (ANDA) | January 30, 2026 |
| Everolimus | 70377-092 | Tablet, for suspension | Generic drugs (ANDA) | January 14, 2026 |
| Everolimus | 70377-091 | Tablet, for suspension | Generic drugs (ANDA) | January 14, 2026 |
| Everolimus | 70377-090 | Tablet, for suspension | Generic drugs (ANDA) | January 14, 2026 |
| Sacubitril and Valsartan | 70377-033 | Tablet, film coated | Generic drugs (ANDA) | July 17, 2025 |
| Sacubitril and Valsartan | 70377-032 | Tablet, film coated | Generic drugs (ANDA) | July 17, 2025 |
| Sacubitril and Valsartan | 70377-031 | Tablet, film coated | Generic drugs (ANDA) | July 17, 2025 |
| Norepinephrine bitartrate | 70377-121 | Injection, solution, concentrate | Generic drugs (ANDA) | July 1, 2025 |
| Everolimus | 70377-112 | Tablet | Generic drugs (ANDA) | June 2, 2025 |
| Everolimus | 70377-071 | Tablet | Generic drugs (ANDA) | June 2, 2025 |
| Everolimus | 70377-070 | Tablet | Generic drugs (ANDA) | June 2, 2025 |
| Everolimus | 70377-069 | Tablet | Generic drugs (ANDA) | June 2, 2025 |
| Micafungin | 70377-076 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 1, 2025 |
| Micafungin | 70377-075 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 1, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.